PLUS THERAPEUTICS, INC. — Investor Relations & Filings

Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's technology platform is designed to deliver high-dose, localized radiation directly to tumors. Its core approach involves encapsulating Rhenium radioisotopes (186Re and 188Re) within nanoliposomes. The lead investigational drug, REYOBIQ™ (rhenium Re186 obisbemeda), is a nanoliposome therapy targeting brain and central nervous system (CNS) cancers, including recurrent glioblastoma and leptomeningeal metastases. A second pipeline program, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is a radioembolization therapy being developed for solid organ cancers, such as liver cancer. The use of Rhenium allows for both therapeutic beta radiation and gamma imaging during treatment.